Biobanks: The unmet need in heart failure management.

[1]  A. Cohen-Solal,et al.  Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology , 2022, European journal of heart failure.

[2]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[3]  I. Komuro,et al.  Clinical Characteristics and Outcomes of Hospitalized Patients With Heart Failure From the Large-Scale Japanese Registry Of Acute Decompensated Heart Failure (JROADHF). , 2021, Circulation journal : official journal of the Japanese Circulation Society.

[4]  S. Solomon,et al.  Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry. , 2020, JAMA cardiology.

[5]  C. Sergi,et al.  The Human Explanted Heart Program: A translational bridge for cardiovascular medicine , 2020, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.

[6]  S. Yusuf,et al.  A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. , 2020, American heart journal.

[7]  S. Petersen,et al.  Cardiovascular research highlights from the UK Biobank: opportunities and challenges. , 2019, Cardiovascular research.

[8]  P. Sandøe,et al.  Broad consent for biobanks is best – provided it is also deep , 2019, BMC Medical Ethics.

[9]  L. Lund,et al.  The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure , 2018, Upsala journal of medical sciences.

[10]  Cathie Sudlow,et al.  UK Biobank: opportunities for cardiovascular research , 2017, European heart journal.

[11]  J. H. Patterson,et al.  Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.

[12]  T. Shiroto,et al.  Characterization of heart failure patients with mid‐range left ventricular ejection fraction—a report from the CHART‐2 Study , 2017, European journal of heart failure.

[13]  G. Filippatos,et al.  Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[14]  P. Ponikowski,et al.  A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT‐CHF , 2016, European journal of heart failure.

[15]  R. Cooke,et al.  Best practice BioBanking of human heart tissue , 2015, Biophysical Reviews.

[16]  P. Hofman,et al.  Sense and nonsense in the process of accreditation of a pathology laboratory , 2015, Virchows Archiv.

[17]  M. Kawana,et al.  Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. , 2010, American heart journal.

[18]  R. Mohler.  TIME Magazine on “10 Ideas Changing the World Right Now” , 2009 .

[19]  M. Pfisterer,et al.  Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.

[20]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[21]  C. O'connor,et al.  Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. , 2004, American heart journal.